WebION-827359 is a chemically modified ASO, 16 nucleotides in length with a phosphorothioate backbone and constrained ethyl (cEt) modifications. In healthy volunteers the ASO was … WebBackground and objective: Atacicept is an inhibitor of the B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), and is being studied in relation to …
multiple doses of ION-827359, an antisense oligonucleotide …
WebCovidResearchTrials by Shray Alag. drug1312: LRX712; Placebo (315) Hydroxychloroquine (101) Azithromycin (35) Placebo oral tablet (29) Tocilizumab (29) Standard of Care (26) Questionnaire (23) Convalescent Plasma (21) Standard of care (19) Ivermectin (18) Favipiravir (17) No intervention (17) Placebos (17) Convalescent plasma (16) Remdesivir … WebThis is a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of ION-827359 in up to 180 participants. The participants will be randomized to receive oral … porsche remote services
A Phase 1/2a Study to Assess the Safety, Tolerability, …
Web20 apr. 2024 · ION-827359 is a 2·5-generation antisense oligonucleotide drug targeted to reduce the ENaC protein. This study evaluated the safety, pharmacokinetics (PK), and … WebResults: ION-827359 was well-tolerated with an acceptable safety profile after multiple inhalations. The rate of adverse events was similar between ION-827359 and placebo … Web3 aug. 2024 · Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ION-827359, an antisense oligonucleotide inhibitor of ENaC, in healthy … irish country music weekends